FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

The FDA approved dupilumab to treat children aged 2 to 11 years with chronic spontaneous urticaria and persistent symptoms ...

The FDA has extended the approval of dupilumab to children aged 2-11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with histamine 1 antihistamines (H1AH), ...

Proportion of patients with complete response (UAS7=0).

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults ...

Dupilumab use in children appears to be tied to a higher incidence of inflammatory eye conditions, including conjunctivitis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 74.3% of children had an allergic asthma phenotype.

Dupilumab significantly reduced exacerbations in adults with chronic obstructive pulmonary disease by approximately 30% compared with placebo, based on data from approximately 900 individuals. Chronic ...

The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...